Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.6282
+0.0662 (11.78%)
At close: Oct 13, 2025, 4:00 PM EDT
0.6300
+0.0018 (0.29%)
After-hours: Oct 13, 2025, 6:33 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $72.10K. In the year 2024, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
38.15
Revenue / Employee
$24,034
Employees
3
Market Cap
8.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 72.10K | - | - |
Dec 31, 2023 | 72.10K | - | - |
Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
Dec 31, 2021 | 71.26K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SILO News
- 5 days ago - Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth - GlobeNewsWire
- 7 days ago - Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) - GlobeNewsWire
- 12 days ago - Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 13 days ago - Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 27 days ago - Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy - GlobeNewsWire
- 4 weeks ago - Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug - GlobeNewsWire
- 5 weeks ago - Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio - GlobeNewsWire
- 7 weeks ago - Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - GlobeNewsWire